CELL SIGNALING TECHNOLOGY INC.

History

Year	Detail
1999	Cell Signaling Technology (CST) is a privately held company headquartered in Danvers, Massachusetts, U.S., founded in 1999 by Michael Comb.
2008	Cell Signaling Technology, Inc., and TTP LabTech collaborated to develop and co-market Antibodies and Acumen Cytometric Assay Solutions for high-content screening and drug discovery.
2009	The company acquired BIOKÉ, B.V., and expanded operations in Europe.
2012	The company develops a novel Monoclonal Antibody Discovery platform. This technology enables the isolation of monoclonal antibodies with antigen-specific activities that recapitulate or surpass those of the original affinity-purified polyclonal antibodies found in the sera of immunized rabbits and mice.
2013	The company was granted a patent for PCR Methods to detect a subset of treatable Non-Small Cell Lung Cancers.
2014	Dako, an Agilent Technologies company, partnered with Cell Signaling Technology to supply antibodies for Dako-branded companion diagnostics products.
2018	The company opened a new office in Shanghai, China. The new facility triples the office and warehouse footprint and features CST's Global Innovation and Training Academy.
2023	The company agreed with Roche to develop and commercialize CDx assays using CST antibodies.
2023	The company partnered with Bio-Techne Corp. to expand the menu of Simple Western-validated antibodies for various targets across multiple disciplines.
2023	Lunaphore partnered with Cell Signaling Technology Inc. to enable CST antibodies on the Lunaphore COMET platform.
2023	The company partnered with Leica Biosystems, a technology company in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of antibodies from CST validated for immunohistochemistry (IHC).
2023	Shanghai WuXi Diagnostics Co.Ltd and Cell Signaling Technology have partnered to develop targeted companion diagnostics (CDx).